drugset / Trial / NCT02312232

Pharmacokinetic Study in Healthy Males

NCT02312232

Phase 1 Completed 20 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104.

Timeline

Start
2014-11
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 12.5 mg
Subject Carbidopa Unknown 25 mg
Subject Levodopa Small molecule 50 mg
Subject Levodopa Small molecule 100 mg
Subject ODM-104 Unknown 100 mg

Indications